Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Media-OutReach Newswire HKSTP Elite Global Inno Day Showcasing Impactful Innovations from Future Unicorns
Media-OutReach Newswire Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine
2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies 2.